Dr. Jeffrey P. Gold, chancellor and executive vice president of biosciences and health affairs and executive dean of the College of Medicine at the University of Toledo
Campus Visit: November 22
Gold has served at the University of Toledo since 2005 and has full leadership responsibility of the clinical, education and research programs of the university’s health sciences, the faculty practice plan and the clinical delivery system. He was key in the 2006 merger of the University of Toledo and Medical University of Ohio, bringing broad groups of stakeholders together around a common mission. Gold has facilitated the development of three interdisciplinary degree-granting schools within the University of Toledo: the School of Biomarker Research and Individual Medicine, the School of Interprofessional Education and Advanced Human Performance, and the School of Health Care Innovation and Business Excellence.
As part of a university-wide capital campaign, Gold has established multiple named professorships, laboratories and hospital/ambulatory facilities. The health sciences now account for roughly half of all university-wide annual giving, several fold what they were ten years ago.
Gold graduated from the Cornell University College of Engineering, where he majored in theoretical and applied mechanics and graduated top in his class. He earned his M.D. from the Weill Cornell College of Medicine and completed his general surgery residency at The New York Hospital and Memorial Hospital where he served at the administrative chief resident; and his cardiothoracic residency training at the Brigham and Women’s Hospital and Boston Children’s Hospital of Harvard Medical School.
Prior to joining the University of Toledo, Gold served at the Albert Einstein College of Medicine and the Weill Cornell Medical College. His areas of interest include academic health system leadership development, development and implementation of national health care policy, access to higher education and health care, enhancing diversity in higher education and academic health care, and patient safety and patient-centered program development. He has strong interest in interprofessional education and advanced simulation overseeing the planning of a remarkable advanced simulation center.
Dr. Robert Califf, vice chancellor for clinical research and director of the Duke Translational Medicine Institute (DTMI) at the Duke University Medical Center
Campus Visit: July 8-10
Califf leads a multifaceted organization focused on the transformation of how discoveries are translated into improved health outcomes. Prior to his role at DTMI, he was the founding director of the Duke Clinical Research Institute (DCRI), a premier academic research organization. He is the editor-in-chief of American Heart Journal, the oldest cardiovascular specialty journal.
Califf completed his undergraduate studies at Duke University in 1973, summa cum laude and Phi Beta Kappa, and later graduated from the Duke University Medical School. After completing his internship and internal medicine residency at the University of California, San Francisco, he returned to Duke for a fellowship in cardiology. He is board-certified in internal medicine and cardiology.
Considered an international leader in the fields of cardiovascular disease treatment, health outcomes, quality of care, and medical economics, Califf is the author or coauthor of more than 1,000 peer-reviewed articles. The Institute for Scientific Information acknowledges him as one of the 10 most-cited authors in the field of medicine. As director of DTMI, Califf’s contribution includes serving as the first co-chair of the Principal Investigators Steering Committee of the NIH Clinical and Translational Science Award.
As the founder and director of DCRI, Califf led many landmark clinical trials in cardiovascular disease. Under his leadership, DCRI grew to an organization of more than 1,000 employees with an annual budget of over $100 million. A leader in clinical research, DCRI collaborates with government agencies, global academic partners, foundations and biotech, pharmaceutical, device, and diagnostics companies to execute clinical trials in a myriad of therapeutic arenas.
Dr. Daniel Wilson, vice president for health affairs and dean of medicine at the University of Florida Health Science Center in Jacksonville
Campus Visit: June 19-21
Wilson has served at the University of Florida since 2012. Prior to that, he was chairman of psychiatry at Creighton University for 11 years, where he was also a professor of psychiatry, neurology and anthropology.
Wilson has a strong research track record, with more than 50 grants as principal investigator. While his primary focus is forensic psychiatry, Wilson’s research agenda ranges from pharmaceutical development to treatment of mood, psychosis and posttraumatic stress disorders.
Prior to his appointments at Creighton, Wilson served as a professor of psychiatry at the
Wilson received his undergraduate degree in anthropology from Yale University, his medical degree from the University of Iowa and a diploma in mental health leadership from Case Western Reserve University. He completed residency in psychiatry as a joint appointee of Harvard Medical School and the Massachusetts General & McLean Hospitals.
By working at the intersection of the fields of medicine, psychiatry and anthropology, Wilson has created hundreds of scholarly articles on a wide cross-section of topics that have earned him worldwide recognition. He has penned more than 200 papers, books, chapters and other scientific communications across a range of subjects including psychiatric diagnosis, psychopharmacology, forensics and evolutionary medicine.
Campus Visit: June 3-5
Meyers oversees the research, teaching, clinical care and community engagement missions of UC Davis’ School of Medicine in coordination with leadership across the UC Davis community. Meyers also is the executive director of medical education and academic planning for the University of California, Merced, where he leads efforts to establish a school of medicine.
Meyers is a proponent of innovative research. He is a director of the Clinical and Translational Science Center’s Research and Education Career Development Program, as well as the Mentored Clinical Research Training Program. He continues research on cancer molecular biology and metastatic cancer, conducting numerous clinical trials on prostate cancer and gene expression in renal cell carcinoma.
Meyers is a longtime leader of the hospice and palliative care movement, establishing programs that are now national models for providing compassionate end-of-life care. He was founding director of the School of Medicine's West Coast Center for Palliative Care. He is also known for his work in “simultaneous care,” a model of care that allows cancer patients with advanced disease to receive both investigational treatments and palliative care.
A UC Davis faculty member since 1982, Meyers is an expert in hematology and oncology, with a special emphasis on the molecular biology of cancer and on clinical trials. His scholarly work includes more than 200 publications, book chapters, editorials and reviews.
Meyers obtained his medical degree from the UC San Francisco School of Medicine and completed his internship and residency training at UC Davis Medical Center.